Guarding the Goods: An Introduction to Antimicrobial Stewardship

Clinical Microbiology Newsletter

Volumn 34, Issue 12, 2012, Pages 93-97

  Wang, Jeffrey S ^a   Bearman, Gonzalo ^a   Edmond, Michael ^a   Stevens, Michael P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; METICILLIN; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC STEWARDSHIP PROGRAM; ARTICLE; CLINICAL PROTOCOL; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; DRUG DOSE; DRUG FORMULATION; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; HOSPITAL MANAGEMENT; HUMAN; LABORATORY; MOLECULAR DIAGNOSIS; NONHUMAN; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCAL BACTEREMIA;

EID: 84861717305     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2012.05.004     Document Type: Article

References (26)

1. Infectious Diseases Society of America (IDSA), Spellberg B., et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 2011, 52(Suppl. 5):S397-S428.
2. Bartlett J.G. A call to arms: the imperative for antimicrobial stewardship. Clin. Infect. Dis. 2011, 53(Suppl. 1):S4-S7.
3. Dellit T.H., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 2007, 44:159-177.
4. Carmeli Y., et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. 2002, 162:2223-2228.
5. Cosgrove S.E., et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 2002, 162:185-190.
6. Engemann J.J., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 2003, 36:592-598.
7. Owens R.C. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn. Microbiol. Infect. Dis. 2008, 61:110-128.
8. Goldmann D.A., et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996, 275:234-240.
9. MacDougall C. Antimicrobial stewardship programs in health care systems. Clin. Microbiol. Rev. 2005, 18:638-656.
10. Institute of Medicine To err is human: building a safer health system 1999, National Academy Press, Washington, DC.
11. National Committee on Clinical Laboratory Standards Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline M-39-A. 2002 2002, National Committee on Clinical Laboratory Standards, Wayne, PA.
12. Trenholme G.M., et al. Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J. Clin. Microbiol. 1989, 27:1342-1345.
13. Romano J. Labs take new role in antibiotic stewardship, championing improved diagnoses, guiding therapy, saving lives and cutting costs. Med. Lab. Obs. 2009, 41:16-18.
14. Bauer K.A., et al. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin. Infect. Dis. 2010, 51:1074-1080.
15. Paterson D.L. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin. Infect. Dis. 2006, 42(Suppl. 2):S90-S95.
16. Ohl C.A., Luther V.P. Antimicrobial stewardship for inpatient facilities. J. Hosp. Med. 2011, 6(Suppl. 1):S4-S15.
17. Burke J.P. Antibiotic resistance - squeezing the balloon?. JAMA 1998, 280:1270-1271.
18. Harbarth S., et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 2003, 115:529-535.
19. Cosgrove S.E., et al. Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers for Disease Control and Prevention's 12 Steps to Prevent Antimicrobial Resistance Among Hospitalized Adults. Infect. Control. Hosp. Epidemiol. 2007, 28:641-646.
20. Sharma P.R., Barman P. Antimicrobial consumption and impact of " Reserve antibiotic indent form" in an intensive care unit. Indian J. Pharmacol. 2010, 42:297-300.
21. Bal A.M., Gould I.M. Antibiotic stewardship: overcoming implementation barriers. Curr. Opin. Infect. Dis. 2011, 24:357-362.
22. Micek S.T., et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
23. Nicolau D.P. Containing costs and containing bugs: are they mutually exclusive?. J. Manag. Care Pharm. 2009, 15(Suppl. 2):S12-S17.
24. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 2007, 44:357-363.
25. Enoch D.A., et al. Outcome for Gram-negative bacteraemia when following restrictive empirical antibiotic guidelines. Q. J. Med. 2011, 104:411-419.
26. Chiu C.H., et al. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr. Infect. Dis. J. 2011, 30:273-278.